Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753856 · ClinicalTrials.gov registry record · Phase 4
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
NCT01753856 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 69 participants.
The verdict
NCT01753856, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how teriparatide or denosumab affects the bone of postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis).
Interventions
- DRUG Denosumab
- DRUG Tetracycline
- DRUG Teriparatide
- DRUG Calcium Supplement
- DRUG Demeclocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753856
The ClinicalTrials.gov registry entry for NCT01753856 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Denosumab is the first listed.
NCT01753856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01753856 about?
NCT01753856 is a clinical study titled "Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis". The purpose of this study is to determine how teriparatide or denosumab affects the bone of postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis).
What is the current status of trial NCT01753856?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01753856?
The interventions under investigation include: Denosumab (DRUG), Tetracycline (DRUG), Teriparatide (DRUG), Calcium Supplement (DRUG), Demeclocycline (DRUG).
Who is sponsoring clinical trial NCT01753856?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.